ADVERTISEMENT

Dolat Capital: Syngene International - Operationally Weak Q2, Expect Traction In H2 FY21 

Dolat Capital: Syngene International - Operationally Weak Q2, Expect Traction In H2 FY21

Syngene International Biology facility (Image: Company website)
Syngene International Biology facility (Image: Company website)
BQ Blue’s special research section collates quality and in-depth equity and economy research reports from across India’s top brokerages, asset managers and research agencies. These reports offer BloombergQuint’s subscribers an opportunity to expand their understanding of companies, sectors and the economy.
To continue reading this story
Subscribe to unlock & enjoy all Members-only benefits

Choose a plan

Renews automatically. Cancel anytime.
Still Not convinced ? Know More